Patents Represented by Attorney Rosemarie R. Wilk-Orescan
-
Patent number: 8318778Abstract: This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a process for preparing such.Type: GrantFiled: January 8, 2008Date of Patent: November 27, 2012Assignee: Novo Nordisk A/SInventors: Anthony Murray, Jesper Lau, Per Vedsø, Lise Brown Christiansen
-
Patent number: 8263634Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.Type: GrantFiled: November 9, 2010Date of Patent: September 11, 2012Assignee: Novo Nordisk A/SInventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedsø, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce-Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswarak Santhosh
-
Patent number: 8202973Abstract: The present invention relates to a novel method for preparing vitamin K-dependent proteins. Furthermore the present invention relates to novel co-transfected eucaryotic host cells and recombinant vectors to be used in this improved method for preparing vitamin K-dependent proteins.Type: GrantFiled: October 2, 2001Date of Patent: June 19, 2012Assignee: Novo Nordisk Health Care AGInventors: Else Marie Nicolaisen, Lars Soegaard Nielsen
-
Patent number: 8158771Abstract: The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described.Type: GrantFiled: February 4, 2010Date of Patent: April 17, 2012Assignee: Novo Nordisk Health Care AGInventors: Thomas Dock Steenstrup, Peder Lisby Norby
-
Patent number: 8148412Abstract: The present invention describes 2,3-di-substituted N-heteroaromatic propionamides, of Formula (I) wherein the substitution at the 3-position is an optionally substituted phenyl ring and the substitution at the 2-position is an alkyl or cycloalkyl group; pharmaceutical compositions comprising the same; and, methods of using the same. The propionamides are glucokinase activators for the treatment of type II diabetes.Type: GrantFiled: December 5, 2005Date of Patent: April 3, 2012Assignee: Novo Nordisk A/SInventors: Lone Jeppesen, Marit Kristiansen
-
Patent number: 8138185Abstract: This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a process for preparing such.Type: GrantFiled: January 8, 2008Date of Patent: March 20, 2012Assignee: Novo Nordisk A/SInventors: Anthony Murray, Jesper Lau, Per Vedsø
-
Patent number: 8063081Abstract: This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.Type: GrantFiled: October 31, 2007Date of Patent: November 22, 2011Assignee: Novo Nordisk A/SInventors: Dharma Rao Polisetti, Janos Tibor Kodra, Jesper Lau, Paw Bloch, Maria Carmen Valcarce Lopez, Niels Blume, Mustafa Guzel, Kalpathy Chidambareswaran Santhosh, Adnan M. M. Mjalli, Robert Carl Andrews, Govindan Subramanian, Michael Ankersen, Per Vedso, Anthony Murray, Lone Jeppesen
-
Patent number: 7999114Abstract: This invention relates to dicycloalkylcarbamoyl ureas of formula (I), which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.Type: GrantFiled: July 7, 2006Date of Patent: August 16, 2011Assignee: Novo Nordisk A/SInventors: Anthony Murray, Jesper Lau, Per Vedso, Lone Jeppesen, Marit Kristiansen
-
Patent number: 7897734Abstract: The present invention relates to a process for the purification of a protease.Type: GrantFiled: September 15, 2005Date of Patent: March 1, 2011Assignee: Novo Nordisk Healthcare AGInventor: Janus Krarup
-
Patent number: 7897628Abstract: This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.Type: GrantFiled: October 31, 2007Date of Patent: March 1, 2011Assignee: Novo Nordisk A/SInventors: Dharma Rao Polisetti, Janos Tibor Kodra, Jesper Lau, Paw Bloch, Maria Carmen Valcarce Lopez, Niels Blume, Mustafa Guzel, Kalpathy Chidambareswaran Santhosh, Adnan M.M. Mjalli, Robert Carl Andrews, Govindan Subramanian, Michael Ankersen, Per Vedso, Anthony Murray, Lone Jeppesen
-
Patent number: 7884181Abstract: The invention provides a pharmaceutical formulation and a method for preparing the formulation.Type: GrantFiled: October 5, 2005Date of Patent: February 8, 2011Assignee: Novo Nordisk A/SInventors: Petter Lybeck (Berglund), Charlotte Hammelev, Lone Eskildsen, Johanne Madsen, Helle Aalund Olsen, Lone Kimer
-
Patent number: 7884210Abstract: The invention provides a compound of general formula (I) wherein the compounds are of the class ureido-thiazole glucokinase activators, useful for the treatment of various diseases, for example, type 2 diabetes.Type: GrantFiled: July 14, 2006Date of Patent: February 8, 2011Assignee: Novo Nordisk A/SInventors: Jesper Lau, Anthony Murray, Per Vedso, Marit Kristiansen, Lone Jeppesen
-
Patent number: 7879893Abstract: The present invention relates to novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer having the formula A-B-C-D-X (III), wherein: A is a chemical group which reversibly binds to a HisB10 Zn2+ sites of an insulin hexamer; B is a linker; C is a fragment consisting of 0 to 5 neutral amino acids; D is a fragment comprising 1 to 20 positively charged groups independently selected from amino or guanidino groups; and X is —OH, —NH2 or a diamino group. The present invention also relates to R-state insulin hexamers comprising such ligands, and aqueous insulin preparations comprising such R-state insulin hexamers.Type: GrantFiled: September 13, 2002Date of Patent: February 1, 2011Assignee: Novo Nordisk A/SInventors: Helle Birk Olsen, Niels C. Kaarsholm, Peter Madsen, Soren Ostergaard, Svend Ludvigsen, Palle Jakobsen, Anders Klarskov Petersen, Dorte Bjerre Steensgaard
-
Patent number: 7872139Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.Type: GrantFiled: August 8, 2008Date of Patent: January 18, 2011Assignee: Novo Nordisk A/SInventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedsø, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce-Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswaram Santhosh
-
Patent number: 7851636Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.Type: GrantFiled: April 9, 2010Date of Patent: December 14, 2010Assignee: Novo Nordisk A/SInventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedsø, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce-Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswaram Santhosh
-
Patent number: 7598391Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.Type: GrantFiled: June 14, 2006Date of Patent: October 6, 2009Assignee: Novo Nordisk A/SInventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedsø, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce-Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswaran Santhosh
-
Patent number: 7582769Abstract: Dicycloalkyl urea glucokinase activators compounds are glucokinase inhibitors useful for the treatment of diabetes.Type: GrantFiled: July 7, 2006Date of Patent: September 1, 2009Assignee: Novo Nordisk A/SInventors: Anthony Murray, Jesper Lau, Per Vedso, Marit Kristiansen, Lone Jeppesen
-
Patent number: 7576062Abstract: Disclosed are compounds of formula I wherein R1, R2, R5, R6, R7, R8, G, J, L, M, a, b, c, d, e, and f are as defined in the specification, and compositions containing them. These compounds are useful for treating medical disorders resulting from a deficiency in growth hormone.Type: GrantFiled: June 7, 2005Date of Patent: August 18, 2009Assignee: Novo Nordisk A/SInventors: Bernd Peschke, Birgit Richter, legal representative, Thomas Hansen Kruse, Michael Ankersen, Lutz Richter
-
Patent number: 7541373Abstract: This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.Type: GrantFiled: March 1, 2006Date of Patent: June 2, 2009Assignee: Novo Nordisk A/SInventors: Dharma Rao Polisetti, Janos Tibor Kodra, Jesper Lau, Paw Bloch, Mustafa Guzel, Kalpathy Chidambareswaran Santhosh, Adnan M. M. Mjalli, Robert Carl Andrews, Govindan Subramanian, Michael Ankersen, Per Vedso, Anthony Murray, Lone Jeppesen, Jesper Lau
-
Patent number: 7384967Abstract: This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.Type: GrantFiled: October 6, 2003Date of Patent: June 10, 2008Assignee: Novo Nordisk A/SInventors: Dharma Rao Polisetti, Janos Tibor Kodra, Jesper Lau, Paw Bloch, Mustafa Guzel, Kalpathy Chidambareswaran Santhosh, Adnan M. M. Mjalli, Robert Carl Andrews, Govindan Subramanian, Michael Ankersen, Per Vedso, Anthony Murray, Lone Jeppesen